2021 |
12/13 | 15:30 再生誘導医薬候補S 005151一般名:レダセムチドの急性期脳梗塞患者を対象とした第2相臨床試験の良好な結果について |
12/10 | 7,765 | 7,802 | 7,657 | 7,700 | -1.4% | 1,414,500 | 2兆3992億 | +0.52% |
12/09 | 7,800 | 7,856 | 7,715 | 7,809 | +1.51% | 1,360,700 | 2兆4331億 | +1.97% |
12/08 | 7,670 | 7,715 | 7,594 | 7,693 | +1.89% | 1,274,500 | 2兆3970億 | +0.58% |
12/07 | 15:00 新型コロナウイルスの下水疫学調査における変異解析サービスの開始について |
12/07 | 7,531 | 7,587 | 7,425 | 7,550 | +0.23% | 1,460,200 | 2兆3524億 | -1.22% |
12/06 | 7,729 | 7,774 | 7,464 | 7,533 | -0.87% | 1,178,600 | 2兆3471億 | -1.37% |
12/03 | 18:00 新型コロナウイルス感染症(COVID-19)ワクチンS-268019の国内追加免疫試験開始のお知らせ |
12/03 | 7,602 | 7,612 | 7,412 | 7,599 | -0.78% | 1,598,700 | 2兆3677億 | -0.42% |
12/02 | 7,774 | 7,860 | 7,659 | 7,659 | -2.07% | 1,649,300 | 2兆3864億 | +0.43% |
12/01 | 7,949 | 8,028 | 7,810 | 7,821 | -1.29% | 1,696,600 | 2兆4369億 | +2.65% |
11/30 | 13:00 吸収合併による子会社の再編について |
11/30 | 8,175 | 8,184 | 7,920 | 7,923 | -2% | 3,132,000 | 2兆4686億 | +4.21% |
11/29 | 8,084 | 8,331 | 8,044 | 8,085 | -0.1% | 2,422,000 | 2兆5191億 | +6.55% |
11/26 | 8,260 | 8,260 | 7,973 | 8,093 | -2.67% | 2,219,900 | 2兆5216億 | +7.01% |
11/25 | 8,125 | 8,439 | 8,117 | 8,315 | +3.05% | 2,761,900 | 2兆5908億 | +10.22% |
11/25 | 8:30 新型コロナウイルス感染症を含む感染症対策に関するベトナム政府との基本合意書の締結について |
11/24 | 8,021 | 8,157 | 7,987 | 8,069 | -0.17% | 2,057,400 | 2兆5141億 | +7.34% |
11/22 | 7,906 | 8,120 | 7,890 | 8,083 | +2.73% | 2,610,700 | 2兆5185億 | +7.79% |
11/19 | 7,580 | 7,893 | 7,565 | 7,868 | +3.38% | 2,871,100 | 2兆4515億 | +5.14% |
11/18 | 7,508 | 7,641 | 7,480 | 7,611 | +2.16% | 1,578,200 | 2兆3714億 | +1.83% |
11/17 | 7,407 | 7,472 | 7,385 | 7,450 | -0.65% | 1,332,900 | 2兆3213億 | -0.35% |
11/16 | 7,491 | 7,563 | 7,468 | 7,499 | +0.29% | 834,000 | 2兆3365億 | +0.25% |
11/15 | 7,419 | 7,485 | 7,378 | 7,477 | +1.19% | 692,300 | 2兆3297億 | -0.07% |
11/12 | 7,348 | 7,425 | 7,334 | 7,389 | +1.27% | 1,098,600 | 2兆3023億 | -1.19% |
11/11 | 7,202 | 7,313 | 7,202 | 7,296 | +1.46% | 1,022,100 | 2兆2733億 | -2.38% |
11/10 | 7,189 | 7,233 | 7,152 | 7,191 | +0.11% | 763,100 | 2兆2406億 | -3.8% |
11/09 | 7,069 | 7,249 | 7,019 | 7,183 | +1.35% | 1,499,300 | 2兆2381億 | -4.02% |
11/08 | 7,277 | 7,311 | 7,011 | 7,087 | -5.73% | 3,406,000 | 2兆2082億 | -5.51% |
11/05 | 7,595 | 7,625 | 7,430 | 7,518 | -1.7% | 1,679,900 | 2兆3425億 | +0.01% |
11/04 | 7,625 | 7,668 | 7,560 | 7,648 | +0.78% | 1,472,600 | 2兆3830億 | +1.68% |
11/02 | 7,548 | 7,596 | 7,447 | 7,589 | +0.52% | 1,504,100 | 2兆3646億 | +1.09% |
11/01 | 13:00 2022年3月期第2四半期決算補足資料 |
11/01 | 13:00 2021年度第2四半期(上期)決算説明会 |
11/01 | 13:00 2022年3月期第2四半期決算短信[IFRS](連結) |
11/01 | 7,484 | 7,559 | 7,443 | 7,550 | +1.93% | 1,801,100 | 2兆3524億 | +0.77% |
10/29 | 7,380 | 7,415 | 7,302 | 7,407 | +0.67% | 956,100 | 2兆3079億 | -1.06% |
10/28 | 7,430 | 7,430 | 7,320 | 7,358 | -1.67% | 1,140,300 | 2兆2926億 | -1.75% |
10/27 | 7,504 | 7,568 | 7,443 | 7,483 | -0.03% | 894,000 | 2兆3315億 | -0.09% |
10/26 | 7,435 | 7,518 | 7,428 | 7,485 | +0.75% | 943,300 | 2兆3322億 | -0.01% |
10/25 | 7,471 | 7,494 | 7,416 | 7,429 | -1.3% | 898,900 | 2兆3147億 | -0.76% |
10/22 | 7,541 | 7,616 | 7,501 | 7,527 | +0.6% | 1,159,800 | 2兆3453億 | +0.49% |
10/21 | 11:30 新型コロナウイルス感染症(COVID-19)ワクチンS-268019の第2⁄3相臨床試験開始のお知らせ |
10/21 | 7,618 | 7,653 | 7,432 | 7,482 | -1.79% | 1,730,300 | 2兆3312億 | -0.09% |
10/20 | 7,652 | 7,676 | 7,610 | 7,618 | -0.18% | 1,114,300 | 2兆3736億 | +1.68% |
10/19 | 7,620 | 7,653 | 7,568 | 7,632 | +0.34% | 748,900 | 2兆3780億 | +1.92% |
10/18 | 7,747 | 7,777 | 7,562 | 7,606 | -1.22% | 1,487,200 | 2兆3699億 | +1.67% |
10/15 | 7,645 | 7,729 | 7,617 | 7,700 | +0.82% | 1,294,500 | 2兆3992億 | +3.04% |
10/14 | 7,616 | 7,663 | 7,585 | 7,637 | -0.26% | 1,172,100 | 2兆3795億 | +2.24% |
10/13 | 7,544 | 7,700 | 7,523 | 7,657 | +1.28% | 1,880,200 | 2兆3858億 | +2.59% |
10/12 | 7,543 | 7,584 | 7,492 | 7,560 | +0.21% | 1,024,400 | 2兆3555億 | +1.49% |
10/11 | 7,409 | 7,574 | 7,395 | 7,544 | +2.25% | 1,391,300 | 2兆3506億 | +1.51% |
10/08 | 7,390 | 7,492 | 7,362 | 7,378 | +1.19% | 1,577,300 | 2兆2988億 | -0.49% |
10/07 | 7,332 | 7,362 | 7,272 | 7,291 | -0.48% | 1,098,500 | 2兆2717億 | -1.49% |
10/06 | 7,420 | 7,463 | 7,232 | 7,326 | -0.96% | 2,231,100 | 2兆2826億 | -0.84% |
10/05 | 7,449 | 7,499 | 7,315 | 7,397 | -2.59% | 2,051,800 | 2兆3048億 | +0.35% |
10/04 | 7,640 | 7,733 | 7,521 | 7,594 | +1.25% | 2,533,500 | 2兆3661億 | +3.33% |
10/01 | 15:00 新市場区分「プライム市場」の選択申請に関するお知らせ |
10/01 | 13:30 HIV感染予防における長時間作用型注射剤カボテグラビルの優先審査指定に関するViiV社の発表について |
10/01 | 13:30 1日1回投与2剤配合錠Dovato(ドルテグラビルおよびラミブジン)のTANGO試験144週時点の結果に関するViiV社の発表について |
10/01 | 7,630 | 7,640 | 7,470 | 7,500 | -2.01% | 2,999,900 | 2兆3368億 | +2.43% |
09/30 | 7,480 | 7,745 | 7,420 | 7,654 | +5.37% | 5,888,600 | 2兆3848億 | +4.76% |
09/29 | 7,245 | 7,312 | 7,116 | 7,264 | +0.47% | 2,884,200 | 2兆2633億 | -0.1% |
09/28 | 19:40 Shionogi R&D Day 2021 |
09/28 | 19:00 超長時間作用型薬剤となる第3世代HIVインテグラーゼ阻害剤S-365598の導出に関するViiV Healthcareとのライセンス契約締結について |
09/28 | 11:30 新型コロナウイルス感染症(COVID-19)治療薬S-217622の国内第2⁄3相臨床試験の開始について |
09/28 | 7,319 | 7,325 | 7,134 | 7,230 | -2.13% | 2,369,100 | 2兆2527億 | -0.32% |
09/27 | 7,497 | 7,497 | 7,378 | 7,387 | -1.41% | 1,445,000 | 2兆3016億 | +2.09% |
09/24 | 7,480 | 7,513 | 7,424 | 7,493 | +1.54% | 1,766,800 | 2兆3347億 | +3.9% |
09/22 | 7,392 | 7,440 | 7,347 | 7,379 | +0.11% | 969,300 | 2兆2991億 | +2.87% |
09/21 | 7,354 | 7,425 | 7,324 | 7,371 | -1.77% | 1,669,500 | 2兆2967億 | +3.25% |
09/17 | 7,491 | 7,537 | 7,480 | 7,504 | -0.25% | 1,470,800 | 2兆3381億 | +5.63% |
09/16 | 7,510 | 7,586 | 7,461 | 7,523 | +0.31% | 1,250,200 | 2兆3440億 | +6.48% |
09/15 | 7,500 | 7,593 | 7,480 | 7,500 | -0.68% | 1,467,600 | 2兆3368億 | +6.78% |
09/14 | 7,539 | 7,569 | 7,503 | 7,551 | +0.49% | 1,495,600 | 2兆3527億 | +8.17% |
09/13 | 7,444 | 7,535 | 7,410 | 7,514 | +0.6% | 1,233,600 | 2兆3412億 | +8.32% |
09/10 | 7,290 | 7,491 | 7,280 | 7,469 | +0.97% | 2,552,600 | 2兆3272億 | +8.59% |
09/09 | 7,467 | 7,474 | 7,275 | 7,397 | -2.96% | 3,069,000 | 2兆3048億 | +8.65% |
09/08 | 7,505 | 7,654 | 7,502 | 7,623 | +1.79% | 2,921,500 | 2兆3752億 | +13.12% |
09/07 | 7,401 | 7,658 | 7,400 | 7,489 | +2.87% | 3,587,700 | 2兆3334億 | +12.4% |
09/06 | 7,200 | 7,320 | 7,200 | 7,280 | +2.02% | 2,191,400 | 2兆2683億 | +10.32% |
09/03 | 7,078 | 7,172 | 7,054 | 7,136 | +0.42% | 2,052,200 | 2兆2234億 | +9.15% |
09/02 | 7,055 | 7,130 | 7,039 | 7,106 | +0.79% | 1,776,700 | 2兆2141億 | +9.53% |
09/01 | 6,951 | 7,070 | 6,949 | 7,050 | +1.41% | 2,061,300 | 2兆1966億 | +9.46% |
08/31 | 6,875 | 6,985 | 6,869 | 6,952 | +0.48% | 1,829,300 | 2兆1661億 | +8.68% |
08/30 | 6,784 | 6,920 | 6,760 | 6,919 | +1.13% | 1,697,100 | 2兆1558億 | +8.82% |
08/27 | 6,800 | 6,860 | 6,725 | 6,842 | -1.01% | 2,916,600 | 2兆1318億 | +8.38% |
08/26 | 7,128 | 7,130 | 6,840 | 6,912 | -2.73% | 4,963,900 | 2兆1536億 | +10.26% |
08/25 | 7,000 | 7,230 | 6,870 | 7,106 | +4.65% | 6,456,100 | 2兆2141億 | +14.24% |
08/24 | 15:00 新型コロナウイルス感染症(COVID-19)ワクチンS-268019の新製剤を用いた第1⁄2相臨床試験の進捗に関するお知らせ |
08/24 | 6,771 | 6,824 | 6,720 | 6,790 | -0.24% | 1,782,900 | 2兆1156億 | +10.14% |
08/23 | 6,867 | 6,879 | 6,730 | 6,806 | +0.04% | 1,748,300 | 2兆1206億 | +11.1% |
08/20 | 6,850 | 6,904 | 6,736 | 6,803 | +0.25% | 5,051,200 | 2兆1197億 | +11.73% |
08/19 | 6,550 | 6,894 | 6,534 | 6,786 | +4.08% | 5,330,100 | 2兆1144億 | +12.15% |
08/18 | 6,521 | 6,605 | 6,514 | 6,520 | -0.14% | 1,291,200 | 2兆315億 | +8.45% |
08/17 | 6,510 | 6,600 | 6,486 | 6,529 | +0.74% | 1,625,500 | 2兆343億 | +9.2% |
08/16 | 6,520 | 6,534 | 6,420 | 6,481 | -0.84% | 1,242,100 | 2兆193億 | +8.94% |
08/13 | 6,504 | 6,554 | 6,436 | 6,536 | +0.51% | 1,697,400 | 2兆365億 | +10.37% |
08/12 | 6,454 | 6,563 | 6,353 | 6,503 | +1.1% | 2,715,800 | 2兆262億 | +10.39% |
08/11 | 6,560 | 6,738 | 6,321 | 6,432 | -0.03% | 6,503,200 | 2兆41億 | +9.74% |
08/10 | 6,076 | 6,454 | 6,063 | 6,434 | +6.56% | 5,321,300 | 2兆47億 | +10.28% |
08/06 | 5,773 | 6,099 | 5,765 | 6,038 | +5.5% | 4,171,400 | 1兆8813億 | +3.98% |
08/05 | 5,690 | 5,738 | 5,673 | 5,723 | +0.95% | 597,200 | 1兆7832億 | -1.29% |
08/04 | 5,705 | 5,748 | 5,640 | 5,669 | -0.91% | 1,007,600 | 1兆7663億 | -2.28% |
08/03 | 5,811 | 5,811 | 5,688 | 5,721 | -3% | 1,766,400 | 1兆7825億 | -1.48% |
08/02 | 16:00 2021年度第1四半期決算Conference Call |
08/02 | 16:00 2022年3月期第1四半期業績補足資料 |
08/02 | 16:00 2022年3月期第1四半期決算短信〔IFRS〕(連結) |
08/02 | 5,828 | 5,925 | 5,810 | 5,898 | +2.54% | 812,900 | 1兆8377億 | +1.58% |
07/30 | 5,849 | 5,850 | 5,752 | 5,752 | -2.31% | 1,146,400 | 1兆7922億 | -0.78% |
07/29 | 5,956 | 5,971 | 5,875 | 5,888 | -0.93% | 723,500 | 1兆8346億 | +1.66% |
07/28 | 17:00 ベトナムへの新型コロナウイルス感染症ワクチンの製造に関する技術移管について |
07/28 | 5,939 | 5,988 | 5,894 | 5,943 | -0.12% | 1,002,100 | 1兆8517億 | +2.77% |
07/27 | 6,000 | 6,017 | 5,921 | 5,950 | -0.34% | 1,473,900 | 1兆8539億 | +3.19% |
07/26 | 5,869 | 5,970 | 5,802 | 5,970 | +3.2% | 1,765,900 | 1兆8601億 | +3.74% |
07/26 | 8:30 新型コロナウイルス感染症(COVID-19)治療薬S-217622の臨床試験開始について-経口抗ウイルス薬の国内第1相臨床試験開始- |
07/21 | 16:00 譲渡制限付株式報酬としての自己株式の処分の払込完了について |
07/21 | 5,817 | 5,838 | 5,752 | 5,785 | +0.68% | 868,800 | 1兆8025億 | +0.71% |
07/20 | 5,750 | 5,778 | 5,684 | 5,746 | +0.91% | 1,121,700 | 1兆7903億 | +0.05% |
07/19 | 5,700 | 5,733 | 5,662 | 5,694 | -0.49% | 788,800 | 1兆7741億 | -0.92% |
07/16 | 16:00 がん特異的ペプチドワクチンS-588410の食道がん患者を対象とした第3相臨床試験結果について |
07/16 | 5,757 | 5,771 | 5,713 | 5,722 | -1.72% | 997,400 | 1兆7828億 | -0.47% |
07/15 | 5,911 | 5,929 | 5,806 | 5,822 | -1.17% | 1,012,900 | 1兆8140億 | +1.22% |